FDA DEVICE FACTS
ArteraAI Prostate
Artera, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
ArteraAI Prostate is a software only device intended to analyze scanned histopathology whole slide images (WSIs) from treatment-naïve prostate core needle biopsies prepared from formalin fixed paraffin-embedded (FFPE) tissue and stained using Hematoxylin & Eosin (H&E) stains. ArteraAI Prostate provides 10-year risks of distant metastasis and prostate cancer specific mortality and is intended to assist physicians with prognostic risk-based decisions along with other clinicopathological factors in non-metastatic prostate cancer patients. ArteraAI Prostate is intended for males 55 years of age or older without clinically or pathologically defined metastases, and who are candidates for curative intent management (surgery, radiation therapy with or without systemic therapy, or active surveillance). ArteraAI Prostate is intended to utilize WSIs acquired from an FDA-cleared interoperable scanner with which ArteraAI Prostate has been authorized for use or a 510(k)-cleared scanner that has been assessed in accordance with the Predetermined Change Control Plan (PCCP) for qualifying additional interoperable scanners.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。